Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

IF 5.2 3区医学 Q1 NEUROSCIENCES

Journal of Neuroimmune Pharmacology Pub Date : 2016-12-26 DOI:10.1007/s11481-016-9722-5

Ross Penninkilampi, Holly M. Brothers, G. Eslick

引用次数: 52

查看原文本刊更多论文

抗β淀粉样蛋白免疫疗法治疗阿尔茨海默病的安全性和有效性:一项系统综述和荟萃分析

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuroimmune Pharmacology 医学-神经科学

CiteScore

13.60

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The aims of the Journal of Neuroimmune Pharmacology are to promote the dissemination, interest, and exchange of new and important discoveries for the pharmacology and immunology of the nervous system. The aims parallel that of the Society on NeuroImmune Pharmacology by increasing the fundamental understanding of neurologic and neuropsychiatric disorders affected by the immune system or vice versa and towards pharmacologic measures that lead, either to a better understanding of disease mechanisms, or by improving disease outcomes. The scope of JNIP includes all primary works and reviews into the etiology, prevention, and treatment of neuroimmune and nervous system diseases affected by disordered immunity. Original studies serving to define neuroimmune modulation of environmental or endogenous cues such as toxins and drugs of abuse, hormones, and cytokines are welcome. JNIP will serve as a reliable source of interdisciplinary information bridging the fields of pharmacology, immunology, and neuroscience.